Serum Soluble CD40L Level And Its Application In Coronary Heart Disease

Objective: To investigate the serum of soluble CD40 ligand (sCD40L) in coronary heart disease and its relationship with serum lipid levels and the extent of coronary stenosis, whether upregulation of CD40L system is related to stability of atherosclerotic plaque in patients with acute coronary syndrome. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to measure the level of sCD40L in 64 patients with coronary heart disease (18 with acute myocardial infarction, 19 with unstable angina pectoris and the other 27 with stable angina pectoris ) and 20 matched healthy controls. Coronary stenosis of 29 patients were assessed by angiographic coronary stenosis morphology.Results: sCD40L level was significantly higher in patients with acute coronary syndrome (ACS) 〔(19.8±3.0), (19.6±4.3) ng/mL in acute myocardial infarction and unstable angina pectoris group,respectively〕 than that of those with stable coronary heart disease and that of controls 〔(7.7±3.3) ng/mL and (5.1±1.9) ng/mL, respectively P<0.05〕 . Serum sCD40L level was negatively related to HDL-C (r =-0.26, P=0.017), and positively related to coronary stenosis (r=0.47 P<0.01). Conclution: The levels of sCD40L increase in acute coronary syndrome, which may be related to the pathogenesis of ACS, and can be used as a potential marker of plaque instability, which is positively to the extent of coronary stenosis, inhibitor of CD40L can be used as an important method to heal restenosis.